Resources for Food and Drug Administration (FDA)

FDA funds UA’s valley fever trial

www.gvnews.com

The Office of Orphan Product Development in the Food and Drug Administration has awarded more than $1 million to the University of Arizona’s Valley Fever Center for Excellence.

The grant will help fund Phase One and Phase Two clinical trials for nikkomycin Z, a promising investigational treatment for valley fever.

Additional support for the development of nikkomycin Z has come from the National Institutes of Health, the Critical Path Institute, UA’s BIO5 Institute and New York-based JT Tai & Company Foundation.

Many donations came from individuals, including animal lovers because valley fever also is a major problem for dogs and other pets. Valley fever is a disease of the lungs caused by the fungus coccidioidomycosis that is common in the southwestern United States and northwestern Mexico.

View the Resource

Share or bookmarklet this web page at: